GoldenGolden
Expansion Therapeutics

Expansion Therapeutics

Expansion Therapeutics is a RNA Targeted Small Molecules.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

January 2018
Expansion Therapeutics raises a $55,300,000 series A round from 5AM Ventures, Kleiner Perkins Caufield & Byers, Novartis Venture Fund, RA Capital Management and Sanofi Ventures.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 25, 2021
BioSpace
Expansion Therapeutics, Inc., a biotechnology company advancing transformative medicines to patients with RNA-mediated diseases, today announced the in-licensing of two new research programs from Scripps Research. One program targets tau, a key driver of dementia disorders
May 6, 2021
BioSpace
Expansion Therapeutics Names Valerie Cullen, Ph.D., Senior Vice President of Research - read this article along with other careers information, tips and advice on BioSpace
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.